Anti-immunoglobulin analysis by diffusion patterns of inhibition and facilitation of complementary lysis in agar. II. Diffusion-lysis as a method for recognizing in vivo immunosuppressive activity of anti-immunoglobulins.
This paper provides evidence that it is possible to prepare facilitating anti-mouse immunoglobulin (that is, anti-mouse immunoglobulin which facilitates complementary lysis of red cells sensitized with mouse-produced haemolysin) which, when injected into mice 24 hours before an injection of sheep red cells, very markedly reduced the number of haemolysin-producing cells detectable in spleen four days later. The diffusion-lysis method was used to recognize this and other anti-Ig's in heterologous antiserum and fractions thereof. The effective antibody was in the gamma2 fraction of antiserum produced in guinea pigs by injecting them with guinea pig red cells sensitized with mouse-produced haemolysin. This method of immunizing was used in order to stimulate the production of antibody against immunoglobulin which had undergone the configurational change characteristically occurring when antibody unites with antigen. The 19S fraction of the antiserum contained inhibiting anti-mouse immunoglobulin (anti-mouse immunoglobulin which inhibits complementary lysis of red cells sensitized with mouse-produced haemolysin) and interfered with immune depression by the gamma2 fraction. It is postulated that the gamma2 fraction induces complementary lysis only of lymphocytes whose surface immunoglobulin receptors have bound antigen and undergone configurational change. It is suggested that facilitating anti-immunoglobulin of the type described is responsible for immune suppression by anti-lymphocyte serum (ALS). Facilitating anti-mouse immunoglobulin was demonstrated in two samples of ALS (anti-mouse) which were active in suppressing graft rejection, but inhibiting anti-mouse immunoglobulin only was found in a sample which was ineffective in suppressing graft rejection.
D000362:Agar; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis*; D000921:Antibody-Producing Cells; D005591:Chemical Fractionation; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006168:Guinea Pigs / Q000276:immunology; D006461:Hemolysis; D006462:Hemolytic Plaque Technique; D007106:Immune Sera; D007115:Immunization Schedule; D005779:Immunodiffusion / Q000379:methods*; D007122:Immunoelectrophoresis; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D007165:Immunosuppression Therapy; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D012756:Sheep / Q000276:immunology; D013154:Spleen / Q000166:cytology
D000888:Antibodies, Anti-Idiotypic; D007106:Immune Sera; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D000362:Agar